International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab

Affiliations

• ¹ European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.
• ² Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany.
• ³ Department of Dermatology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
• ⁴ Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
• ⁵ Hidradenitis Suppurativa Unit, Instituto de Investigación Biosanitaria ibs and Servicio de Dermatologia, Hospital Universitario Virgen de Las Nieves, Granada, Spain.
• ⁶ Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
• ⁷ Department of Dermatology, University of Pisa, Pisa, Italy.
• ⁸ Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wrocław, Poland.
• ⁹ Novartis Pharma AG, Basel, Switzerland.
• ¹⁰ Novartis Ireland Limited, Dublin, Ireland.
• ¹¹ Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
• ¹² Department of Dermatology, Nordland Hospital Trust, Bodø, Norway.